ENLV

Enlivex Therapeutics Ltd. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website enlivex.com
Employees(FY) -
ISIN IL0011319527

Performance

-18.33%

-35.79%

-22.54%

-30.78%

-63.85%

YTD

-42.92%

Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Advanced Technical Analysis

Technical Analysis of ENLV 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score at 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ENLV

Stock Rank

Recent News & Updates

2024-11-19 19:00
Enlivex Adopts Bitcoin Treasury Reserve Strategy(Globenewswire)
2024-11-13 19:00
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis(Globenewswire)
2024-11-11 19:00
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis(Globenewswire)
2024-10-31 00:00
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know(Yahoo Finance)
2024-10-29 20:00
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis(Globenewswire)
2024-09-25 20:30
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis(Globenewswire)
2024-09-23 20:30
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis(Globenewswire)
2024-09-11 00:00
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy(Yahoo Finance)
2024-08-29 21:00
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-07-22 20:00
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis(Globenewswire)
2024-07-18 21:00
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-06-23 20:00
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis(Globenewswire)
2024-06-19 20:00
Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25(Globenewswire)
2024-06-16 20:00
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis(Globenewswire)
2024-06-02 20:00
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis(Globenewswire)
2024-05-29 04:15
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering(Globenewswire)
2024-05-27 20:12
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering(Globenewswire)
2024-04-28 20:00
Enlivex CEO Issues Letter to Shareholders Perspectives on Recent Events(Globenewswire)
2024-04-21 20:00
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis(Globenewswire)
2024-04-15 19:50
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis(Globenewswire)
2024-04-15 01:01
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why(Zacks)
2024-04-11 02:58
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra In Patients with Sepsis(Globenewswire)
2024-04-10 20:05
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis(Globenewswire)
2024-04-04 19:52
ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-21 22:50
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-02-25 19:30
Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis(Accesswire)
2024-02-20 19:30
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals(Accesswire)
2024-02-06 19:00
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method(Globenewswire)
2024-01-16 19:00
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis(Globenewswire)
2023-12-19 19:00
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.